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July 2010126 Smithbody code and could represent the removal of a number of
different things. Likewise, you can’t tell if a filter is retrievable or
permanent with NIS data.
Dr Jeffrey Rhodes (Rochester, NY). In one of your slides
toward the end, the diagnosis of filter and pulmonary embolus
combined seemed to drop over the last few years. So even though
there was an increase of prophylactic filter use. It looked like there
was a similar decrease in pulmonary embolus. I guess my question
is: Is that correct?
Dr Moore. I think the slide you are referring to is the one
showing the proportion of vena caval filters that are therapeutic or
prophylactic. The proportion of all vena caval filters that are placed
in combination with pulmonary embolus has actually dropped.
Dr Rhodes. So the question is, although there is a higher
percentage, the absolute number of prophylactic filters has gone
up, and likewise, the number of pulmonary emboli has gone down.
When you figure your cost data, you need to figure out what the
cost of a PE is, because those prophylactic filters may actually be
functional.
The other thing is from a DRG (Diagnosis Related Group)
standpoint, if they have a DVT or pulmonary embolus, I believe
that will increase the DRG. So to use cost basis on outpatient
assumptions doesn’t really give you the true cost, because there is
mind that the UK has a population one-fifth that of the USA, thisactually no more money spent, because the hospital doesn’t get
reimbursed when you have a pulmonary embolus, et cetera, unless
they up-code the DRG. Just as a comment.
Dr Moore. I agree with that. We were just trying to come up
with an estimate that we could feel good about. The cost of filter
placement in an inpatient was too variable to use for this purpose.
Dr Rhodes.No, I understand. Just to make a conclusion that
we are spending too much money, I don’t think, based on the NIS
database that you can accurately do that. That was my concern.
Dr Moore. I understand.
Dr Anil Hingorani (Brooklyn, NY). I am always concerned
about these large data sets fromNIS, or et cetera, about the validity
of the data. Were you able to validate any of this data either
internally or externally?
Dr Moore. There was a paper published in the past using the
national hospital discharge survey to examine filter placement from
1979 to 1999. They showed that it increased from 2000 filters in
1979 to 49,000 filters a year in 1999. Our estimate for 1999 was
around 52,000. That is all the validation I can offer at this time. I
agree that these large databases have some inherent limitations and
you have to take this data with a grain of salt. The absolute
numbers are probably not as important as the trends. I think the
trends are valid.INVITED COMMENTARYPhilip Coleridge Smith, London, United Kingdom
I read this article and was impressed with the efforts of the
authors in extracting data from the databases reflecting medical
practice in theUnited States of America (USA). I was exceptionally
impressed by the number of inferior vena cava (IVC) filters that are
deployed each year, a considerable contrast to medical practice in
the United Kingdom (UK). I expected, at each turn of the page, to
find some outcome data reflecting the value of this policy of
prophylactic use of IVC filters, but was profoundly disappointed
on reaching the end of the article to find no indication of the value
of investing considerable time, effort, and health care funds in
placing these devices. The authors also express scepticism about
the extent of use, especially prophylactic use, of IVC filters. The
simple question I would like the authors to answer is: How many
lives were saved? It is unfortunate that this cannot be deduced from
public domain database information.
Checking publicly available data from the Department of
Health (UK) Hospital Episode Statistics, I found that 474 patients
underwent IVC filter treatment in the UK in 2005. Bearing inamounts to a filter usage one-fiftieth of that of the USA. Even
taking into account the possibilities of coding and other errors in
these data, this reflects a huge difference in medical practice. So
perhaps our impoverished social health care system is failing the
UK population?
I then investigated publicly available information from the
World Health Organization Statistical Information System. I
checked the adult mortality rate (probability of dying between the
age of 15 and 60 years/1000 population) both sexes, for 2006.
This is 80/1000 in the UK and 109/1000 in the USA. These data
clearly do not measure the direct outcome of IVC filter placement
but certainly offer no support to the extensive use of such devices
to prevent death from pulmonary embolism in the USA.
Clinical practice in the USA in this context appears to be based
on the opinion of experts, which can be regarded as level III
evidence, rather than on randomized clinical trials. This has re-
sulted in huge expenditure without clear benefit. The use of IVC
filters deserves much more detailed research to establish their
value.
